How Fe3+ binds anthracycline antitumour compounds -: The myth and the reality of a chemical sphinx

被引:48
作者
Fiallo, MML
Garnier-Suillerot, A
Matzanke, B
Kozlowski, H
机构
[1] Univ Paris 13, CNRS ESA 7033, LPBC, F-93017 Bobigny, France
[2] Univ Lubeck, Isotope Lab Nat Sci, D-2400 Lubeck, Germany
[3] Univ Wroclaw, Fac Chem, PL-50138 Wroclaw, Poland
关键词
circular dichroism; anthracycline; metal complexes; iron(III) coordination; antitumour compounds;
D O I
10.1016/S0162-0134(99)00040-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The interaction of Fe3+ with several anthracycline antitumour antibiotics has been reinvestigated. Absorption and circular dichroism (CD) measurements were carried out (i) in aqueous solution and (ii) in semi-aqueous MeOH to avoid the stacking of the anthracycline molecules. The Fe3+ binding to anthracycline was dependent on the metal-to-ligand molar ratio, antibiotic concentration, ionic strength, and pH. The formation of two major Fe3+-anthracycline complexes, I and II, was observed for all the drugs. These species differed in their coordination modes to the anthracycline ligands. Complex I was a monomeric species, where Fe3+ was bound to the anthracycline through the {C(11)-O-; C(12)=0} chelating site. In complex II, Fe3+ was also bound through the {C(5)=O; C(6)-O-} coordination site. Thus, the antibiotic ligand was acting as a bridge between two metal ions, forming oligomeric (or polymeric) structures. The different degree of association of the anthracyclines could be responsible for the reactivity of the metal ion. In fact, complexes I and II could constitute mononuclear, binuclear or polynuclear Fe3+ species depending on the competitive kinetics of both coordination and hydrolysis of the metal ion. (C) 1999 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:105 / 115
页数:11
相关论文
共 55 条
[1]  
BACHUR NR, 1984, CANCER CHEMOTH PHARM, V12, P5
[2]   ASPECTS OF THE DEGRADATION KINETICS OF DAUNORUBICIN IN AQUEOUS-SOLUTION [J].
BEIJNEN, JH ;
VANDERHOUWEN, OAGJ ;
VOSKUILEN, MCH ;
UNDERBERG, WJM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 31 (1-2) :75-82
[3]   ASPECTS OF THE DEGRADATION KINETICS OF DOXORUBICIN IN AQUEOUS-SOLUTION [J].
BEIJNEN, JH ;
VANDERHOUWEN, OAGJ ;
UNDERBERG, WJM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 32 (2-3) :123-131
[4]   IRON(III) ADRIAMYCIN AND IRON(III) DAUNORUBICIN COMPLEXES - PHYSICOCHEMICAL CHARACTERISTICS, INTERACTION WITH DNA, AND ANTITUMOR-ACTIVITY [J].
BERALDO, H ;
GARNIERSUILLEROT, A ;
TOSI, L ;
LAVELLE, F .
BIOCHEMISTRY, 1985, 24 (02) :284-289
[5]   THERMODYNAMIC AND KINETIC-STUDIES OF HYDROXO AND CHLORO COMPLEXES OF IRON(III) IN ETHANOL WATER MIXTURES [J].
BRIDGER, K ;
PATEL, RC ;
MATIJEVIC, E .
JOURNAL OF PHYSICAL CHEMISTRY, 1983, 87 (07) :1192-1201
[6]   The interactions of Fe3+ ions with adriamycin studied by Fe-57 Mossbauer and electronic spectroscopies [J].
Capolongo, F ;
Giomini, M ;
Giuliani, AM ;
Matzanke, BF ;
Russo, U ;
Silvestri, A ;
Trautwein, AX ;
Barbieri, R .
JOURNAL OF INORGANIC BIOCHEMISTRY, 1997, 65 (02) :115-122
[7]  
DOROSHOW JH, 1983, CANCER RES, V43, P460
[8]  
DRESDALE A, 1983, CANCER, V52, P51, DOI 10.1002/1097-0142(19830701)52:1<51::AID-CNCR2820520111>3.0.CO
[9]  
2-#
[10]   OXIDATIVE DESTRUCTION OF DNA BY THE ADRIAMYCIN IRON COMPLEX [J].
ELIOT, H ;
GIANNI, L ;
MYERS, C .
BIOCHEMISTRY, 1984, 23 (05) :928-936